Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00595062
Recruitment Status : Completed
First Posted : January 16, 2008
Last Update Posted : December 22, 2015
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

This study was started to validate the possibility of administering radiation therapy during surgery to the tissue surrounding the tumor once the tumor has been removed. This surrounding breast tissue is at greater risk for developing breast recurrences. This treatment may be as effective as the conventional 5-6week radiation treatment in reducing the risk of further local recurrences after breast-conserving surgery.

Through this study, we would like to confirm that this procedure is a safe alternative to conventional breast radiation, with no additional side effects when compared with the conventional surgery and radiation therapy.

Condition or disease Intervention/treatment Phase
Breast Cancer Radiation: Intra Operative Radiation Therapy (IORT) Not Applicable

Detailed Description:

This pilot trial will evaluate the feasibility of intra operative radiation therapy (IORT) given in one fraction at the time of wide local excision as the only adjuvant radiation treatment in a group of patients with early-stage invasive breast cancer.

This study will enroll 60 women, older than 60 years of age, with breast cancer not more than 2 cm in size and without evident additional tumoral foci around the tumor or in other areas of the breast. An MSK radiologist will review your mammography to be sure you qualify for this study. You may be asked to undergo additional mammography or other examinations, such as breast ultrasound in order to verify that the tumor is located in a single quadrant of the breast. Some of these procedures are routinely performed in all candidates for conservative breast surgery.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study
Study Start Date : October 2002
Actual Primary Completion Date : January 2006
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Radiation: Intra Operative Radiation Therapy (IORT)
Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)

Primary Outcome Measures :
  1. To determine tissue tolerance of the breast to a single intraoperative course of radiation. [ Time Frame: 7 years ]
  2. To establish feasibility of the technique in the operating room. [ Time Frame: 7 years ]

Secondary Outcome Measures :
  1. overall survival [ Time Frame: 7 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Core biopsy or prior open biopsy to establish the diagnosis.
  • Over age 60.
  • No physical or imaging evidence of multicentricity or multifocality.
  • Size equal or less than 2.0 cm radiographically, clinically node negative.
  • Patients scheduled for breast conserving surgery

Exclusion Criteria:

  • Patients younger than 61 years
  • Patients with evidence of multicentric or multifocal disease seen on imaging (mammography )
  • Patients with a lesion exceeding 2 cm radiographically
  • Paget's disease or pure DCIS without invasive ductal carcinoma
  • Histotype not inclusive of ductal carcinoma
  • Condition precluding radiation therapy
  • Condition precluding regular follow-up
  • Evident dimpling of the skin above the tumor
  • Usual contraindications for BCS

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00595062

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Principal Investigator: Beryl McCormick, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00595062     History of Changes
Other Study ID Numbers: 02-101
First Posted: January 16, 2008    Key Record Dates
Last Update Posted: December 22, 2015
Last Verified: December 2015

Keywords provided by Memorial Sloan Kettering Cancer Center:

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases